Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Blau Farmacêutica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Blau Farmacêutica şirketinin toplam hissedar öz sermayesi R$2.0B ve toplam borcu R$519.5M olup, bu da borç-öz sermaye oranını 25.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla R$3.1B ve R$1.1B dir. Blau Farmacêutica 'in FAVÖK'ü R$312.7M faiz karşılama oranı 129.4 dur. Şirketin R$376.4M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

25.5%

Borç/özkaynak oranı

R$519.48m

Borç

Faiz karşılama oranı	129.4x
Nakit	R$376.38m
Eşitlik	R$2.03b
Toplam yükümlülükler	R$1.06b
Toplam varlıklar	R$3.10b

Son finansal sağlık güncellemeleri

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Recent updates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BLAU3 'nin kısa vadeli varlıkları ( R$1.5B ) kısa vadeli yükümlülüklerini ( R$376.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: BLAU3 şirketinin kısa vadeli varlıkları ( R$1.5B ) uzun vadeli yükümlülüklerini ( R$687.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BLAU3 'nin net borç/öz sermaye oranı ( 7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: BLAU3 'nin borç/öz sermaye oranı son 5 yılda 79.2% seviyesinden 25.5% seviyesine düştü.

Borç Kapsamı: BLAU3 'nin borcu işletme nakit akışı ( 45.7% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: BLAU3 'in borcuna ilişkin faiz ödemeleri EBIT ( 129.4 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Blau Farmacêutica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Recent updates

Investor sentiment improves as stock rises 15%

Price target increased by 10% to R$14.00

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.29 in 1Q 2023)

Price target decreased by 9.1% to R$14.29

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin